0001209191-23-042654.txt : 20230718
0001209191-23-042654.hdr.sgml : 20230718
20230718191423
ACCESSION NUMBER: 0001209191-23-042654
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230718
DATE AS OF CHANGE: 20230718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coulie Bernard
CENTRAL INDEX KEY: 0001808895
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39303
FILM NUMBER: 231095319
MAIL ADDRESS:
STREET 1: C/O PLIANT THERAPEUTICS, INC.
STREET 2: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001746473
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474272481
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-481-6770
MAIL ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-14
0
0001746473
PLIANT THERAPEUTICS, INC.
PLRX
0001808895
Coulie Bernard
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
0
Common Stock
2023-07-14
4
A
0
137500
0.00
A
412253
D
Common Stock
409317
I
See footnote
On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 137,500 shares.
Shares are held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
/s/ Mike Ouimette, attorney-in-fact
2023-07-18